10.1111/tpj.12081 177 YangY
Because it contains 0.9% benzyl alcohol which prevents bacterial growth and supports safe multiple withdrawals making it the more stable and reliable choice for medication dilution and peptide reconstitution
[DOI] [PMC free article] [PubMed] [Google Scholar] 157.Lu C.C., Huang W.S., Lee K.F., Lee K.C., Hsieh M.C., Huang C.Y., Lee L.Y., Lee B.O., Teng C.C., Shen C.H., et al
The result in phase 2 clinical trials was 24.2% mean body weight reduction at 48 weeks with the 12mg dose, and the first phase 3 TRIUMPH-4 trial reported an average of 28.7% weight loss at 68 weeks
While these findings are encouraging, its important for our patients to understand that robust human clinical trials are still lacking